Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.53 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bemcentinib, ningetinib, bpi-9016 +4 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 5 Parkinson's papers of 3,485 | 0.76 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11469
Earlier readings: 2026-10-26 0.39; 2026-10-25 0.39; 2026-10-24 0.39; 2026-10-23 0.39.
Sealed predictions
- AXL in dopamine neurons, braak-0.47 (p 0.197) → -0.33 (p 0.380)receipt 0173
Swarm cases
receipt 0173: AXL in dopamine neurons, braak
- power
- full sample -0.35 (p 0.156, n 18), 95% CI -0.70 to +0.14. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.176, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.225, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.26, sign flips 0; without severely affected donors -0.35 (p 0.156, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AXL in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts